A Review on Quantitative Process Analytical Technology for Continuous Downstream Processing of Monoclonal Antibodies

Review (2025)
Author(s)

Mariana Carvalho (TU Delft - BT/Bioprocess Engineering)

Ana Cruz (Johnson & Johnson)

Cees Haringa (TU Delft - BT/Bioprocess Engineering)

Marcel Ottens (TU Delft - BT/Design and Engineering Education)

Marieke Klijn (TU Delft - BT/Bioprocess Engineering)

Research Group
BT/Bioprocess Engineering
DOI related publication
https://doi.org/10.1002/bit.70139
More Info
expand_more
Publication Year
2025
Language
English
Research Group
BT/Bioprocess Engineering
Issue number
3
Volume number
123
Pages (from-to)
564-581
Reuse Rights

Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.

Abstract

The competition in the biopharmaceutical market is increasing due to the market entry of biosimilars and rising costs in research and development of new drugs. Hence, continuous manufacturing gained significant attention due to its potential in reducing production cycle times and costs, as well as the possibility of real-time release testing. As a consequence, active monitoring and/or control systems are required for quantitative product quality measurements and in-process control. Process analytical technology emerged as a robust strategy for the development and implementation of in situ real-time testing, instead of the standard batch testing of end product. Through the evaluation of state-of-the-art applications, this review highlights future opportunities in the field of quantitative real-time analytical techniques for the characterization of monoclonal antibodies in continuous downstream biomanufacturing.